Mast Group has introduced the latest in vitro diagnostics (IVD) solutions from Seegene, a developer of multiplex IVD products. A revolution in real-time PCR, Allplex enables high-capacity multiplexing with quantitative reporting.
Seegene's innovative proprietary technologies, including DPO, TOCE and MuDT, can detect up to 28 targets per sample simultaneously, with no post-PCR processing, and provides high sensitivity, specificity, and reproducibility.
Allplex assays use next-generation real-time PCR technology (MuDT). Seegene offers a comprehensive range of CE-marked assays including a 26-target Respiratory Full Panel, a 25-target Gastrointestinal Infection Full Panel and a 28-target Sexually Transmitted Infection Full Panel. MuDT allows detection and quantification of multiple target analytes simultaneously in a single fluorescence channel, without melt curve analysis after amplification. The Allplex assays can be a vital tool in accurate and cost-effective syndrome-based diagnosis within the clinical environment.
Allplex assays benefits include: high-capacity multiplexing with real-time PCR (no post-PCR analysis required); enhanced syndromic management of patients through accurate and effective detection of mixed infections; complete range of viral, parasitic and bacterial pathogens; and end-to-end solution for laboratories with full sample tracking, processing and reporting
